DK0393438T3 - TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor - Google Patents
TNF-receptor, TNF-bindende proteiner og DNAér, der koder herforInfo
- Publication number
- DK0393438T3 DK0393438T3 DK90106624T DK90106624T DK0393438T3 DK 0393438 T3 DK0393438 T3 DK 0393438T3 DK 90106624 T DK90106624 T DK 90106624T DK 90106624 T DK90106624 T DK 90106624T DK 0393438 T3 DK0393438 T3 DK 0393438T3
- Authority
- DK
- Denmark
- Prior art keywords
- tnf
- tnf receptor
- receptor
- binding protein
- binding proteins
- Prior art date
Links
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title abstract 6
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title abstract 6
- 108020004414 DNA Proteins 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/144—Tumor necrosis factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3913101A DE3913101A1 (de) | 1989-04-21 | 1989-04-21 | Tnf-(alpha) bindende proteine und dafuer kodierende dnas |
| DE19893920282 DE3920282A1 (de) | 1989-06-21 | 1989-06-21 | Tnf-rezeptor, tnf bindende proteine und dafuer kodierende dnas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0393438T3 true DK0393438T3 (da) | 2005-05-30 |
Family
ID=25880137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK90106624T DK0393438T3 (da) | 1989-04-21 | 1990-04-06 | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US6294352B1 (da) |
| EP (1) | EP0393438B1 (da) |
| AT (1) | ATE289350T1 (da) |
| DE (1) | DE59010941D1 (da) |
| DK (1) | DK0393438T3 (da) |
| ES (1) | ES2238070T3 (da) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512544A (en) * | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
| IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| US5811261A (en) * | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
| DK0393438T3 (da) * | 1989-04-21 | 2005-05-30 | Amgen Inc | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor |
| US6221675B1 (en) | 1989-04-21 | 2001-04-24 | Amgen, Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
| US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
| IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
| US20030225254A1 (en) | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
| US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| JP3443119B2 (ja) * | 1989-08-07 | 2003-09-02 | ペプテック リミテッド | 腫瘍壊死因子結合リガンド |
| NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| GB2246569A (en) * | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
| GB9022648D0 (en) * | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| SG63617A1 (en) * | 1991-01-18 | 1999-03-30 | Amgen Boulder Inc | Methods for treating tumar necrosis factor mediated diseases |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| CA2107340C (en) * | 1991-06-19 | 2003-06-10 | Gunther Adolf | Monoclonal antibodies against human tnf-binding protein i (tnf-bp i) |
| WO1993004375A1 (en) * | 1991-08-23 | 1993-03-04 | Nchip, Inc. | Burn-in technologies for unpackaged integrated circuits |
| JP3122139B2 (ja) * | 1991-10-15 | 2001-01-09 | マラーキー，ミッシェル，エフ． | 後期段階炎症反応の治療用組成物 |
| IL101769A (en) * | 1992-05-03 | 2007-02-11 | Yeda Res & Dev | Modulation of TNF receptor action |
| US6579697B1 (en) * | 1995-05-11 | 2003-06-17 | Yeda Research And Development Co. Ltd. | Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors |
| US5847099A (en) * | 1994-10-19 | 1998-12-08 | Genetics Institute, Inc. | TNF receptor death domain ligand proteins |
| US5712381A (en) | 1994-10-19 | 1998-01-27 | Genetics Institute, Inc. | MADD, a TNF receptor death domain ligand protein |
| US7427492B1 (en) | 1995-06-05 | 2008-09-23 | Human Genome Sciences, Inc. | Polynucleotides encoding human tumor necrosis factor receptor-like2 |
| US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
| JPH11507205A (ja) * | 1995-04-27 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体 |
| DE69739656D1 (de) | 1996-02-09 | 2009-12-31 | Amgen Inc | 1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe |
| KR970065714A (ko) * | 1996-03-11 | 1997-10-13 | 성재갑 | 종양 괴사 인자 수용체의 세포질내 도메인 단백질 및 이의 변형체 |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| EP0960196A4 (en) * | 1996-10-04 | 2002-10-29 | Immunex Corp | CELL DEATH CAUSING RECEPTOR |
| JP2001502912A (ja) * | 1996-10-30 | 2001-03-06 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子レセプター―ライク２ |
| ES2615357T3 (es) | 1996-12-06 | 2017-06-06 | Amgen Inc. | Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1 |
| US6893838B1 (en) | 1998-04-07 | 2005-05-17 | Genetics Institute Llc | DADD, death activator death domain protein |
| WO2000021981A2 (de) * | 1998-10-09 | 2000-04-20 | Bioserv Ag | TNFα BINDENDE PEPTIDE UND IHRE ANWENDUNG FÜR DIE DETEKTION, INAKTIVIERUNG UND/ODER ENTFERNUNG VON TNFα AUS BIOLOGISCHEN FLÜSSIGKEITEN |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6475987B1 (en) * | 1999-05-06 | 2002-11-05 | National Jewish Medical And Research Center | Tall-1 receptor homologues |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| AU4541101A (en) | 2000-03-02 | 2001-09-12 | Xencor Inc | Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| BR0001078A (pt) * | 2000-04-06 | 2003-05-13 | Maria Amalia Rotolo De Moraes | Método e aparelho de estìmulo positivo mental |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| CA2421588C (en) | 2000-09-05 | 2010-01-26 | Amgen Inc. | Tnf receptor-like molecules and uses thereof |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| DE10059616A1 (de) * | 2000-12-01 | 2002-06-06 | Zimmer Ag | Verfahren zum Erzeugen von Polycarbonaten |
| EP1414517A4 (en) * | 2001-06-26 | 2008-02-06 | Photomed Technologies Inc | MULTIPLE WAVELENGTH ILLUMINATOR |
| ES2706902T3 (es) | 2001-06-26 | 2019-04-01 | Amgen Inc | Anticuerpos para OPGL |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| CA2466298A1 (en) * | 2001-11-30 | 2003-06-05 | Applied Research Systems Ars Holding N.V. | Methods of increasing protein expression levels |
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| AR042038A1 (es) * | 2002-11-15 | 2005-06-08 | Ares Trading Sa | Procedimiento para la purificacion de proteinas de union al factor de necrosis tumoral |
| US7384744B2 (en) | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| US7344886B2 (en) | 2002-11-29 | 2008-03-18 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| AU2003299971A1 (en) * | 2002-12-30 | 2004-07-29 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20050008640A1 (en) * | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
| JP2008509692A (ja) * | 2004-08-16 | 2008-04-03 | ノボ ノルディスク アクティーゼルスカブ | ペプチドの多量体 |
| BRPI0518762A2 (pt) * | 2004-12-02 | 2008-12-09 | Domantis Ltd | fusço de droga, conjugado de droga, Ácido nucleico recombinante ou isolado, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir a fusço de droga, composiÇço farmacÊutica, mÉtodo para tratamento de um indivÍduo tendo uma doenÇa inflamatària, uso de um conjugado de droga ou fusço de droga, e, composiÇço de droga |
| KR101789603B1 (ko) * | 2005-11-10 | 2017-11-21 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물 |
| US7785834B2 (en) * | 2005-11-10 | 2010-08-31 | Ercole Biotech, Inc. | Soluble TNF receptors and their use in treatment of disease |
| PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
| US8007790B2 (en) | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| US20090264353A1 (en) * | 2007-10-19 | 2009-10-22 | Santaris Pharma A/S | Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease |
| EP1953222A1 (en) | 2007-01-24 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of cell growth |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| WO2010010108A1 (en) * | 2008-07-23 | 2010-01-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improved production host cell lines |
| US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
| CA2777162A1 (en) * | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Polypeptides that bind il-23r |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| IN2012DN06720A (da) | 2010-01-15 | 2015-10-23 | Kirin Amgen Inc | |
| PL2657252T3 (pl) | 2010-12-23 | 2017-08-31 | Hanall Biopharma Co., Ltd. | Modyfikowany polipeptyd ludzkiego receptora-1 czynnika martwicy nowotworu lub jego fragment i sposób ich wytwarzania |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| WO2014102101A1 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
| WO2014102103A2 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Heterologous intron within a signal peptide |
| SG11201607881SA (en) | 2014-03-31 | 2016-10-28 | Kirin Amgen Inc | Methods of treating nail and scalp psoriasis |
| US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
| IL268007B2 (en) | 2017-01-30 | 2025-05-01 | Janssen Biotech Inc | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
| AU2017398101B2 (en) | 2017-02-07 | 2025-02-06 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
| CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| EP4596046A3 (en) | 2020-05-21 | 2025-10-22 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN150740B (da) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| US4560649A (en) * | 1981-10-15 | 1985-12-24 | Cornell Research Foundation | Assaying for hLH or hCG with immobilized hormone receptors |
| JPH0751511B2 (ja) * | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン２を含有してなる癌治療剤 |
| US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4966888A (en) * | 1985-07-08 | 1990-10-30 | Cornell Research Foundation, Inc. | hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine |
| EP0154316B1 (en) * | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| CA1339269C (en) * | 1984-05-21 | 1997-08-12 | Douglas P. Cerretti | Purification of and cloning of the gene for interleukin-2 receptor |
| US4578335A (en) * | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
| US4675285A (en) * | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| CA1283046C (en) * | 1986-05-29 | 1991-04-16 | Nandini Katre | Tumor necrosis factor formulation |
| US4693684A (en) * | 1986-05-30 | 1987-09-15 | Johnson & Johnson Dental Products Company | Ratchet type dispenser for dental materials |
| US4931544A (en) * | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
| IL80005A (en) * | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
| IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US5512544A (en) * | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5153265A (en) * | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| GB8806339D0 (en) * | 1988-03-17 | 1988-04-13 | Hoffmann La Roche | Monoclonal antibodies |
| GB8807803D0 (en) * | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
| US5214131A (en) * | 1988-05-06 | 1993-05-25 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, modified peptides and production thereof |
| IL92697A (en) * | 1989-12-13 | 1996-03-31 | Yeda Res & Dev | Molecular cloning of TNF binding protein |
| IL94039A (en) * | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
| US5811261A (en) * | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
| US5359037A (en) * | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
| US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5089261A (en) * | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| DE3920282A1 (de) * | 1989-06-21 | 1991-01-03 | Boehringer Ingelheim Int | Tnf-rezeptor, tnf bindende proteine und dafuer kodierende dnas |
| DK0393438T3 (da) * | 1989-04-21 | 2005-05-30 | Amgen Inc | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor |
| DE3913101A1 (de) * | 1989-04-21 | 1990-10-31 | Boehringer Ingelheim Int | Tnf-(alpha) bindende proteine und dafuer kodierende dnas |
| DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
| CA2017025C (en) * | 1989-05-18 | 2008-07-22 | David Wallach | Tumor necrosis factor binding protein ii, its purification and antibodies thereto |
| IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| GB8919598D0 (en) * | 1989-08-30 | 1989-10-11 | Exxon Chemical Patents Inc | Coating compositions |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| AU630497B2 (en) * | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
| DE10399023I2 (de) * | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| DK0433900T3 (da) * | 1989-12-13 | 1996-01-29 | Yeda Res & Dev | Ekspression af rekombinant tumornekrosefaktor bindingsprotein I (TBP-I) |
| US5136021A (en) * | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
| FI87492C (fi) | 1990-06-12 | 1993-01-11 | Valmet Paper Machinery Inc | Foerfarande och anordning foer maetning och reglering av bestrykningsmaengden |
| GB2246569A (en) * | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
| WO1992001002A1 (en) * | 1990-07-11 | 1992-01-23 | Teijin Limited | Tumor necrosis factor activity inhibitor and production thereof |
| EP0540612A1 (en) * | 1990-07-20 | 1993-05-12 | Pharmacia AB | Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
| GB9022648D0 (en) * | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| SG63617A1 (en) * | 1991-01-18 | 1999-03-30 | Amgen Boulder Inc | Methods for treating tumar necrosis factor mediated diseases |
| DE69233068T2 (de) * | 1991-02-27 | 2004-01-22 | Micromet Ag | Serin-reiche peptidlinker |
| ES2199935T3 (es) * | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| IL99120A0 (en) * | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| JPH07504203A (ja) * | 1992-09-15 | 1995-05-11 | イミュネックス・コーポレーション | 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法 |
| US5359307A (en) * | 1993-08-12 | 1994-10-25 | Hewlett-Packard Corporation | High voltage relay |
-
1990
- 1990-04-06 DK DK90106624T patent/DK0393438T3/da active
- 1990-04-06 ES ES90106624T patent/ES2238070T3/es not_active Expired - Lifetime
- 1990-04-06 AT AT90106624T patent/ATE289350T1/de not_active IP Right Cessation
- 1990-04-06 DE DE59010941T patent/DE59010941D1/de not_active Expired - Fee Related
- 1990-04-06 EP EP90106624A patent/EP0393438B1/de not_active Expired - Lifetime
-
1995
- 1995-02-01 US US08/383,676 patent/US6294352B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/484,307 patent/US6440693B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/484,312 patent/US6271346B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/477,638 patent/US6417158B1/en not_active Expired - Lifetime
-
2001
- 2001-07-03 US US09/899,429 patent/US20020169118A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1017820A1 (en) | 1999-11-26 |
| US6294352B1 (en) | 2001-09-25 |
| US6417158B1 (en) | 2002-07-09 |
| US6271346B1 (en) | 2001-08-07 |
| EP0393438A3 (de) | 1991-06-19 |
| EP0393438A2 (de) | 1990-10-24 |
| US20020169118A1 (en) | 2002-11-14 |
| ES2238070T3 (es) | 2005-08-16 |
| DE59010941D1 (de) | 2005-03-24 |
| ATE289350T1 (de) | 2005-03-15 |
| US6440693B1 (en) | 2002-08-27 |
| EP0393438B1 (de) | 2005-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0393438T3 (da) | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor | |
| Iida et al. | β2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis | |
| ATE113295T1 (de) | Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren. | |
| DE60140773D1 (de) | Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS) | |
| IL94039A0 (en) | Antibodies to anti-cytotoxic proteins | |
| DE69232309D1 (de) | Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen | |
| ATE80180T1 (de) | Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels ''protein-engineering''. | |
| PT100344A (pt) | Factores polipeptidicos mitogenicos gliais, e seu processo de preparacao, ensaio da actividade mitogenica, sequencias de adn que codificam os factores e construcoes de adn que as compreendem, celulas hospedeiras, formulacoes farmaceutica ou veterinaria, uso dos polipeptidos, anticorpo, e sequencia genetica codificando actividade mitogenica de celulas gliais. | |
| DK0597503T3 (da) | ECK-receptorligander | |
| AU6250098A (en) | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l) | |
| NO20084906L (no) | DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer | |
| EE9800322A (et) | TNF retseptoriga seotud faktori (TRAF) modulaatorid, nende valmistamine ja kasutamine | |
| Porschke et al. | The change of DNA structure by specific binding of the cAMP receptor protein from rotation diffusion and dichroism measurements. | |
| EP1985705A3 (en) | Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections | |
| IS3197A7 (is) | Magnbundin ákvörðun kjarnasýrusameinda og samstæðefni notuð við hana | |
| PT84089B (pt) | Sequencias de adn codificando para proteinas possuindo a actividade biologica dos inibidores de husi-tipo i, processos biotecnologicos para a preparacao das referidas proteinas e de composicoes farmaceuticas contendo as referidas proteinas | |
| DK71986D0 (da) | Polypeptider fra rhinovirusstamme hrv2 samt de herfor kodende dna-molekyler, fremgangsmaade til polypeptidernes fremstilling og deres anvendelse | |
| Fossard et al. | Separation of the proteins of cerebrospinal fluid using gel electrofocusing followed by electrophoresis | |
| BR9712793A (pt) | Fatores homólogos (fhfs) ao fator do desenvolvimento de fibroblasto e métodos de uso | |
| FI940036A0 (fi) | Nukleotidisekvenssejä ja sykloheksimidiresistenssejä proteiineja | |
| SE8901342L (sv) | Biologiska material, foerfaranden foer framstaellning av biologiska material samt foer anvaendning av saadana material i terapi | |
| SG128403A1 (en) | Tnf-receptors, tnf binding proteins and dnas coding for them | |
| ATE187202T1 (de) | Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung | |
| ATE162224T1 (de) | Crf bindungsproteine | |
| DK0524421T3 (da) | Humant herpesvirus type 6 protein p 100, de tilsvarende DNA-sekvenser, deres fremstilling og anvendelse |